



21 January 2022

Appendix 3Y – Late Lodgement

Melbourne, Australia, Friday 21 January 2022 – Opyl Limited (ASX:OPL) advises the following in relation to the late lodgement of Appendix 3Y in respect of the announcement of change of Director's Interest for Dr Megan Robertson:

- The Appendix 3Y has been lodged late due to an administrative oversight.
- The Company took immediate steps to address this oversight on realisation that the Appendix 3Y has not been lodged within the prescribed period.
- The Company advises that it is aware of its Listing Rules obligations in relation to these disclosures and specifically Listing Rule 3.19A and 3.19B.
- The Company has put in place an update to its set procedure to ensure that the Company and its Directors are able to meet their disclosure obligations under Listing Rule 3.19A and 3.19B.
- The Company has reviewed its previous procedures and now considers that its revised arrangements are adequate for ensuring timely notification and compliance.

The Board has authorised this announcement for release to the ASX.

-ENDS-

For media enquiries: Laura Blue +61 416 699 925

For investor enquiries: info@opyl.ai

www.opyl.ai

Opyl is a new generation Australian company that provides leading biopharma and health organisations access to emerging AI-assisted technologies and real-world data insights to understand and improve healthcare and clinical research design, development, and delivery.

Opyl works at the intersection of clinical trials, artificial intelligence, and social media.

Our key offering for biopharma, medtech, government and healthcare organisations:

- clinical trial recruitment solutions
- clinical trial predictive analytics and protocol design
- deep social media insights and analysis

Our vision is to improve health and wellness by optimising data assets and digital activation to advance technologies for life.

Follow Opyl on Twitter (@Opylai), LinkedIn and Facebook

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Opyl Limited
ABN 71 063 144 865

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Megan Robertson
Date of last notice	5 May 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Megan Robertson Pty Ltd <Megan Robertson P/L S/F A/C>
Date of change	24 December 2021
No. of securities held prior to change	1. 300,000 Unlisted options (100,000 with exercise price \$0.30, 100,000 with exercise price \$0.50, and 100,000 with exercise price \$0.75, and expiry date 10 December 2026)
Class	Fully paid ordinary shares
Number acquired	46,901 Fully paid ordinary shares

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	46,900 shares at 11.5 cents per share, and 1 share at 11 cents per share
No. of securities held after change	<ol style="list-style-type: none"> 46,901 Fully paid ordinary shares 300,000 Unlisted options (100,000 with exercise price \$0.30, 100,000 with exercise price \$0.50, and 100,000 with exercise price \$0.75, and expiry date 10 December 2026)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market share purchase

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Interest disposed	N/A
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.